Sun Pharma.Inds. Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 24 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.6L Cr
Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
From Sun Pharma.Inds.'s Q2 FY26 earnings-call transcript · updated 24 Aug 2026.
Price
₹1,902.4
Market Cap
₹4.6L Cr
P/E Ratio
36.1
How does Sun Pharma.Inds. rank in Pharmaceuticals & Biotechnology?
Compare Sun Pharma.Inds. against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sun Pharma.Inds. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹14.6K Cr, net profit ₹2.7K Cr.
Full financials →📊 Revenue & Sales Performance
- →Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue.
- →U.S. Innovative Medicine sales have surpassed generics for the first time, indicating growth focus.
- →India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches.
- →Specialty products like ILUMYA expected to continue prescription growth due to expanding markets.
- →Targeted treatments like Leqselvi market expected to grow with increasing prescriber confidence and payer coverage.
- →GLP-1 market described as very exciting with expected growth; Sun Pharma aims to participate actively.
- →New product launches (e.g., Unloxcyt) supported by $100 million incremental spend, with anticipation of increased expenses into H2 FY26.
- →Overall, the company anticipates continued growth in innovative medicines and specialty segments, with generics business being stable but lower growth.
📈 Profitability & Margins
- →Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
- →Specialty product launches (Leqselvi, Unloxcyt) will increase related sales and marketing expenses into H2 FY26 and beyond, supporting growth.
- →U.S. Innovative Medicines sales are surpassing generics, indicating growth emphasis on higher-value specialty medicines.
- →Continued growth expected for ILUMYA and specialty biologics in the U.S. and global markets.
- →The company remains competitive in emerging GLP-1 market, aiming to participate at first opportunity once patents expire; long-term growth anticipated here.
- →R&D spend expected at lower end of 6%-8% guidance, possibly improving pipeline but controlling costs.
- →Cash flow expected to normalize by year-end after working capital and acquisition-related impacts.
- →Overall, cautious optimism with growth driven by innovative medicines and specialty portfolio, supported by disciplined cost and investment management.
🏗️ Capital Expenditure Plans
- →Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17).
- →Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12).
- →Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6).
- →Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6).
- →Manufacturing footprint in the U.S. is being constantly assessed with openness to increase U.S.-based manufacturing given policy developments (Page 16, 11).
- →No detailed disclosures on capacity plans for GLP-1 drugs or innovative molecules yet (Page 16).
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Sun Pharma.Inds. Q2 FY26 results?
Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
What is Sun Pharma.Inds. share price analysis?
Sun Pharma.Inds. currently shows a neutral. The stock trades at a P/E of 36.1 with a market cap of ₹456,449 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma.Inds. planning capital expenditure?
Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17). - Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12). - Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6). - Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6). - Manufacturing footprint in the U.S.
Keep Sun Pharma.Inds. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.